Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances
J Cell Immunol
.
2021;3(6):387-396.
doi: 10.33696/immunology.3.122.
Authors
Yilun Deng
1
,
Ryan M Reyes
2
3
,
Chenghao Zhang
1
4
,
José Conejo-Garcia
5
,
Tyler J Curiel
1
2
3
6
Affiliations
1
Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
2
South Texas Medical Scientist Training Program, University of Texas Health San Antonio, San Antonio, TX, USA.
3
Mays Family Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
4
Xiangya Medical School, Central South University, Changsha, Hunan, China.
5
H. Lee Moffitt Cancer Research Institute, Department of Immunology, Tampa, FL, USA.
6
Graduate School of Biomedical Sciences, University of Texas Health San Antonio, San Antonio, TX, USA.
PMID:
36968176
PMCID:
PMC10035448
DOI:
10.33696/immunology.3.122
No abstract available
Keywords:
IL-2; IL-2 receptor; Immunotherapy; Ovarian cancer; Regulatory T cell.
Grants and funding
T32 AG021890/AG/NIA NIH HHS/United States
T32 GM113896/GM/NIGMS NIH HHS/United States
KL2 TR000118/TR/NCATS NIH HHS/United States
TL1 TR002647/TR/NCATS NIH HHS/United States
P30 CA054174/CA/NCI NIH HHS/United States
R01 CA205965/CA/NCI NIH HHS/United States